Mayo Foundation for Medical Education and Research

University of California

University of Minnesota

Euroimmun Medizinische Labordiagnostika Ag

Cz Biohub Sf, Llc.

Vanda A Lennon

Thomas J Kryzer

Sean J Pittock

Andrew McKeon

Shannon Hinson

Josephe A Honorat

Boyan Fang

Lars Komorowski

Gregory A Worrell

Yvonne Denno

Haidong Dong

Ramona Miske

Madeleine Scharf

Christiane Radzimski

Joseph L DeRisi

Stefanie Hahn

Mandy Unger

Edward H Lambert

Guy E Griesmann

Caleigh Mandel-Brehm

Michael R Wilson

Brian O'Donovan

Divyanshu Dubey

Hai-Long Wang

Lynn T Bemis

Avi Gadoth

Richard G Melvin

James P Fryer

This disclosure describes methods and compositions for detecting the presence of a Kelch-like protein 11 autoantibody in a biological sample. Also provided are methods of treating subjects with testicular cancer or a premalignant condition and paraneoplastic encephalomyelitis.

Autoantibodies as biomarker of paraneoplastic encephalitis associated with testicular cancer

This document provides methods and materials involved in identifying and treating autoimmune GFAP (glial fibrillary acidic protein) astrocytopathy, a novel meningoencephalomyelitis, in humans as well as methods and materials for identifying and offering early treatment for patients having autoimmune GFAP astrocytopathy whose autoantibody profile predicts a high likelihood of having underlying cancer (e.g., adenocarcinoma or teratoma).

Methods and materials for identifying and treating autoimmune GFAP astrocytopathy

Methods for modulating the release and content of extracellular vesicles from target cells using electrical stimulation are provided. Compositions comprising extracellular vesicles or extracts of extracellular vesicles and methods of administering the compositions to a subject are also provided.

Modulation of extracellular vesicles with electrical stimulation

A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.

Autoantibodies to Septin-7 and diagnosis of neurological disease

Methods and materials herein are useful for assessing and/or treating autoimmune ataxias associated with septin-specific autoantibodies (e.g., septin-5-specific autoantibodies). For example, septin-5 polypeptides are provided as well as methods for using septin-5 polypeptides to detect septin-5-specific autoantibodies and/or to treat a mammal having an autoimmune ataxia.

Assessing and treating autoimmune ataxia

This document provides methods and materials for detecting PCA-2-specific autoantibodies, which can be associated with paraneoplastic neurological disorders and cancers associated with PCA-2-specific autoantibodies.

Materials and methods for evaluating and treating cancer

The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.

Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive

The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).

Neuromyelitis optica autoantibodies as a marker for neoplasia

Methods of treating neuromyelitis optica (NMO)

Method of detecting a neuromyelitis optica specific-autoantibody by an antigenic aquaporin-4 polypeptide

Marker for neuromyelitis optica

An immunoassay for small cell lung carcinoma is provided which uses small cell lung carcinoma voltage-gated calcium channel antigen (SCC-VGCC Ag) comprising a detectable label and antibodies against SCC-VGCC Ag to detect endogenous SCC-VGCC Ag.

Immunoassay for small cell lung carcinoma

Growing community of inventors

Rochester, MN, United States of America

Vanda A Lennon